For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Zymeworks BC Inc (NASDAQ: ZYME) was $12.93 for the day, up 1.09% from the previous closing price of $12.79. In other words, the price has increased by $1.09 from its previous closing price. On the day, 0.7 million shares were traded. ZYME stock price reached its highest trading level at $13.0 during the session, while it also had its lowest trading level at $12.635.
Ratios:
Our analysis of ZYME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On November 07, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $10 to $25.
Wells Fargo Downgraded its Overweight to Equal Weight on November 01, 2024, while the target price for the stock was maintained at $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 18 ’25 when EcoR1 Capital, LLC bought 113,880 shares for $12.65 per share. The transaction valued at 1,440,855 led to the insider holds 16,972,298 shares of the business.
EcoR1 Capital, LLC bought 58,306 shares of ZYME for $737,233 on Mar 19 ’25. The Director now owns 17,030,604 shares after completing the transaction at $12.64 per share. On Mar 17 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 56,277 shares for $12.23 each. As a result, the insider paid 688,465 and bolstered with 16,858,418 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 899629312 and an Enterprise Value of 692387072. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.89 while its Price-to-Book (P/B) ratio in mrq is 2.65. Its current Enterprise Value per Revenue stands at 9.074 whereas that against EBITDA is -6.126.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.15, which has changed by 0.22908747 over the last 52 weeks, in comparison to a change of 0.08190584 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -5.80%, while the 200-Day Moving Average is calculated to be 3.92%.
Shares Statistics:
ZYME traded an average of 530.08K shares per day over the past three months and 827820 shares per day over the past ten days. A total of 68.96M shares are outstanding, with a floating share count of 67.30M. Insiders hold about 4.07% of the company’s shares, while institutions hold 96.81% stake in the company. Shares short for ZYME as of 1740700800 were 3963020 with a Short Ratio of 7.48, compared to 1738281600 on 4380063. Therefore, it implies a Short% of Shares Outstanding of 3963020 and a Short% of Float of 7.39.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
